

[ Thu, Nov 28th 2024
] - Tim Hastings
[ Thu, Nov 28th 2024
] - Brian Stokes
[ Thu, Nov 28th 2024
] - Brian Stokes
[ Thu, Nov 28th 2024
] - Bill Williamson
[ Thu, Nov 28th 2024
] - Brian Stokes
[ Thu, Nov 28th 2024
] - Brian Stokes
[ Thu, Nov 28th 2024
] - Phil Bruner
[ Thu, Nov 28th 2024
] - Phil Bruner
[ Thu, Nov 28th 2024
] - Tim Hastings
[ Thu, Nov 28th 2024
] - Tim Hastings
[ Thu, Nov 28th 2024
] - Thomas Matters
[ Thu, Nov 28th 2024
] - Bill Williamson
[ Thu, Nov 28th 2024
] - Phil Bruner
[ Thu, Nov 28th 2024
] - Phil Bruner
[ Thu, Nov 28th 2024
] - Tim Hastings
[ Thu, Nov 28th 2024
] - Thomas Matters
[ Thu, Nov 28th 2024
] - Brian Stokes
[ Thu, Nov 28th 2024
] - Brian Stokes
[ Thu, Nov 28th 2024
] - Brian Stokes
[ Thu, Nov 28th 2024
] - Terrence Williams
[ Thu, Nov 28th 2024
] - Terrence Williams
[ Thu, Nov 28th 2024
] - Michael Jones
[ Thu, Nov 28th 2024
] - Bill Williamson
[ Thu, Nov 28th 2024
] - Bill Williamson
[ Thu, Nov 28th 2024
] - Brian Stokes
[ Thu, Nov 28th 2024
] - Terrence Williams
[ Thu, Nov 28th 2024
] - Phil Bruner
[ Thu, Nov 28th 2024
] - Phil Bruner
[ Thu, Nov 28th 2024
] - Tim Hastings
[ Thu, Nov 28th 2024
] - Bill Williamson
[ Thu, Nov 28th 2024
] - Bill Williamson
[ Thu, Nov 28th 2024
] - Bill Williamson
[ Thu, Nov 28th 2024
] - Brian Stokes
[ Thu, Nov 28th 2024
] - Michael Jones
[ Thu, Nov 28th 2024
] - Michael Jones
[ Thu, Nov 28th 2024
] - Tim Hastings
[ Thu, Nov 28th 2024
] - Aaron Neefham
[ Thu, Nov 28th 2024
] - Aaron Neefham
[ Thu, Nov 28th 2024
] - Aaron Neefham
[ Thu, Nov 28th 2024
] - Thomas Matters
[ Thu, Nov 28th 2024
] - Thomas Matters
[ Thu, Nov 28th 2024
] - Thomas Matters
[ Thu, Nov 28th 2024
] - Brian Stokes
[ Thu, Nov 28th 2024
] - Brian Stokes
[ Thu, Nov 28th 2024
] - Terrence Williams
[ Thu, Nov 28th 2024
] - Michael Jones
[ Thu, Nov 28th 2024
] - Brian Stokes
[ Thu, Nov 28th 2024
] - Brian Stokes
[ Thu, Nov 28th 2024
] - Terrence Williams
[ Thu, Nov 28th 2024
] - Terrence Williams
[ Thu, Nov 28th 2024
] - Michael Jones
[ Thu, Nov 28th 2024
] - Phil Bruner
[ Thu, Nov 28th 2024
] - Bill Williamson
[ Thu, Nov 28th 2024
] - Bill Williamson
[ Thu, Nov 28th 2024
] - Bill Williamson
[ Thu, Nov 28th 2024
] - Bill Williamson
[ Thu, Nov 28th 2024
] - Bill Williamson
[ Thu, Nov 28th 2024
] - Brian Stokes
[ Thu, Nov 28th 2024
] - Phil Bruner
[ Thu, Nov 28th 2024
] - Michael Jones
[ Thu, Nov 28th 2024
] - Thomas Matters
[ Thu, Nov 28th 2024
] - Brian Stokes
[ Thu, Nov 28th 2024
] - Phil Bruner
[ Thu, Nov 28th 2024
] - Phil Bruner
[ Thu, Nov 28th 2024
] - Phil Bruner
[ Thu, Nov 28th 2024
] - Thomas Matters
[ Thu, Nov 28th 2024
] - Thomas Matters
[ Thu, Nov 28th 2024
] - Bill Williamson
[ Thu, Nov 28th 2024
] - Bill Williamson
[ Thu, Nov 28th 2024
] - Terrence Williams
[ Thu, Nov 28th 2024
] - Michael Jones
[ Thu, Nov 28th 2024
] - Michael Jones
[ Thu, Nov 28th 2024
] - Phil Bruner
[ Thu, Nov 28th 2024
] - Phil Bruner
[ Thu, Nov 28th 2024
] - Bill Williamson
[ Thu, Nov 28th 2024
] - Bill Williamson
[ Thu, Nov 28th 2024
] - Brian Stokes
[ Thu, Nov 28th 2024
] - Terrence Williams
[ Thu, Nov 28th 2024
] - Tim Hastings
[ Thu, Nov 28th 2024
] - Thomas Matters
[ Thu, Nov 28th 2024
] - Thomas Matters
[ Thu, Nov 28th 2024
] - Thomas Matters
[ Thu, Nov 28th 2024
] - Bill Williamson
[ Thu, Nov 28th 2024
] - Brian Stokes
[ Thu, Nov 28th 2024
] - Hubert Carizone
[ Thu, Nov 28th 2024
] - Brian Stokes
[ Thu, Nov 28th 2024
] - Thomas Matters
[ Thu, Nov 28th 2024
] - Brian Stokes
[ Thu, Nov 28th 2024
] - Phil Bruner
[ Thu, Nov 28th 2024
] - Phil Bruner
[ Thu, Nov 28th 2024
] - Bill Williamson
[ Thu, Nov 28th 2024
] - Thomas Matters
[ Thu, Nov 28th 2024
] - Thomas Matters
[ Thu, Nov 28th 2024
] - Thomas Matters
[ Thu, Nov 28th 2024
] - Brian Stokes
[ Thu, Nov 28th 2024
] - Brian Stokes
[ Thu, Nov 28th 2024
] - Phil Bruner
[ Thu, Nov 28th 2024
] - Phil Bruner
[ Thu, Nov 28th 2024
] - Tim Hastings
[ Thu, Nov 28th 2024
] - Tim Hastings
[ Thu, Nov 28th 2024
] - Tim Hastings
[ Thu, Nov 28th 2024
] - Thomas Matters
[ Thu, Nov 28th 2024
] - Bill Williamson
[ Thu, Nov 28th 2024
] - Brian Stokes
[ Thu, Nov 28th 2024
] - Brian Stokes
[ Thu, Nov 28th 2024
] - Terrence Williams
[ Thu, Nov 28th 2024
] - Terrence Williams
[ Thu, Nov 28th 2024
] - Michael Jones
[ Thu, Nov 28th 2024
] - Phil Bruner
[ Thu, Nov 28th 2024
] - Tim Hastings
[ Thu, Nov 28th 2024
] - Tim Hastings
[ Thu, Nov 28th 2024
] - Aaron Neefham
[ Thu, Nov 28th 2024
] - Thomas Matters
[ Thu, Nov 28th 2024
] - Hubert Carizone
[ Thu, Nov 28th 2024
] - Phil Bruner
[ Thu, Nov 28th 2024
] - Tim Hastings
[ Thu, Nov 28th 2024
] - Tim Hastings
[ Thu, Nov 28th 2024
] - Aaron Neefham
[ Thu, Nov 28th 2024
] - Aaron Neefham
[ Thu, Nov 28th 2024
] - Thomas Matters
[ Thu, Nov 28th 2024
] - Bill Williamson
[ Thu, Nov 28th 2024
] - Bill Williamson
[ Thu, Nov 28th 2024
] - Bill Williamson
[ Thu, Nov 28th 2024
] - Bill Williamson
[ Thu, Nov 28th 2024
] - Brian Stokes
[ Thu, Nov 28th 2024
] - Bill Williamson
[ Thu, Nov 28th 2024
] - Brian Stokes
[ Thu, Nov 28th 2024
] - Brian Stokes

[ Wed, Nov 27th 2024
] - Phil Bruner
[ Wed, Nov 27th 2024
] - Aaron Neefham
[ Wed, Nov 27th 2024
] - Aaron Neefham
[ Wed, Nov 27th 2024
] - Aaron Neefham
[ Wed, Nov 27th 2024
] - Hubert Carizone
[ Wed, Nov 27th 2024
] - Hubert Carizone
[ Wed, Nov 27th 2024
] - Phil Bruner
[ Wed, Nov 27th 2024
] - Thomas Matters
[ Wed, Nov 27th 2024
] - Thomas Matters
[ Wed, Nov 27th 2024
] - Thomas Matters
[ Wed, Nov 27th 2024
] - Hubert Carizone
[ Wed, Nov 27th 2024
] - Phil Bruner
[ Wed, Nov 27th 2024
] - Terrence Williams
[ Wed, Nov 27th 2024
] - Michael Jones
[ Wed, Nov 27th 2024
] - Tim Hastings
For those with CTE, family history of mental illness tied to aggression in middle age
- People who have chronic traumatic encephalopathy (CTE) who have a family history of mental illness may have a higher risk of aggression in middle age, according to a new study.
The article from ScienceDaily discusses a study published in the journal *Nature Communications* that explores the potential of using a common cold virus, specifically a genetically modified adenovirus, to treat glioblastoma, an aggressive form of brain cancer. Researchers from the University of Alberta found that this virus, when injected directly into the tumor, not only targets and kills cancer cells but also stimulates an immune response that could help prevent cancer recurrence. The virus was modified to enhance its cancer-killing properties while reducing its ability to cause disease in healthy cells. Initial results from a small clinical trial showed promising outcomes, with some patients experiencing significant tumor reduction and prolonged survival. The study suggests that this virotherapy could be a new avenue for treating glioblastoma, potentially offering a less invasive and more targeted approach compared to traditional treatments like chemotherapy and radiation.
Read the Full Science Daily Article at [ https://www.sciencedaily.com/releases/2024/11/241127165716.htm ]
Read the Full Science Daily Article at [ https://www.sciencedaily.com/releases/2024/11/241127165716.htm ]